PFIZER- PHASE 3 STUDY SHOWS XTANDI® (ENZALUTAMIDE) PLUS LEUPROLIDE IMPROVES METASTASIS-FREE SURVIVAL IN MEN WITH NON-METASTATIC PROSTATE CANCER